Cellerant Therapeutics
Research - San Carlos, California, United States
Cellerant Therapeutics Employees
Cellerant Therapeutics Details
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant's romyelocel-L is a universal cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. In a randomized, controlled Phase 2 clinical trial in AML patients, romyelocel-L reduced infections and days in hospital. Cellerant is developing two novel antibody drug-conjugate (ADC) products: CLT030 to treat AML by selectively targeting and killing leukemic stem and blast cells, and CSC012-ADC for hematologic malignancies and solid tumor indications.
